Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2008-08-15
2010-11-09
Bunner, Bridget E (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S008100, C514S012200, C514S173000, C514S401000, C514S532000
Reexamination Certificate
active
07829596
ABSTRACT:
A method of treating weight loss due to underlying disease in a patient, the method comprising administering to the patient an effective amount of an agent which reduces sympathetic nervous system activity. A method of treating weight loss due to underlying disease in a patient, the method comprising administering to the patient an effective amount of any one or more of the following: a compound which inhibits the effect of aldosterone such as an aldosterone antagonist; a chymase inhibitor; a cathepsin B inhibitor; a β receptor blocker; an imidazoline receptor antagonist; a centrally acting α receptor antagonist; a peripherally acting α receptor antagonist; a ganglion blocking agent; a drug that has an effect on cardiovascular reflexes and thereby reduces SNS activity such as an opiate; scopolamine; an endothelin receptor antagonist; and a xanthine oxidize inhibitor. The methods are particularly useful in treating cardiac cachexia.
REFERENCES:
patent: 5541188 (1996-07-01), Maltin
patent: 6545040 (2003-04-01), Xhonneux et al.
patent: 6855729 (2005-02-01), Dinan
patent: 7354941 (2008-04-01), Marfat et al.
patent: 7417038 (2008-08-01), Anker et al.
patent: 2007/0149465 (2007-06-01), Kenley et al.
patent: 0 334 429 (1989-09-01), None
patent: 0 714 663 (1996-06-01), None
patent: 1 990 049 (2008-11-01), None
patent: 09 071 586 (1997-03-01), None
patent: WO 96/24373 (1996-08-01), None
patent: WO 98/15267 (1998-04-01), None
patent: WO 99/02142 (1999-01-01), None
patent: WO 2006/030306 (2006-03-01), None
patent: WO 2006/034343 (2006-03-01), None
patent: WO 2006/102476 (2006-09-01), None
patent: WO 2007/100775 (2007-09-01), None
patent: WO 2008/055940 (2008-05-01), None
patent: WO 2008/093148 (2008-08-01), None
patent: WO 2008/129308 (2008-10-01), None
patent: WO 2009/111648 (2009-09-01), None
Schobel et al, Hypertension, 1995, vol. 25, pp. 1075-1082; pp. 1-11 in PDF format.
Anker, et al., “Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia,”Circulation, 96(2): 526-534 (1997).
Chilian, et al., “Adrenergic coronary tone during submaxial exercise in the dog is produced by circulating catecholamines. Evidence for adrenergic denervation supersensitivity in the myocardium but not in coronary vessels,”Cir. Res., 58(1): 68-82 (1986).
Chua, et al., “The reproducibility and comparability of tests of the peripheral chemoreflex: comparing the transient hypoxic ventilatory drive test and the single-breath carbon dioxide response test in healthy subjects,”Eur. J. Clin. Invest., 25(12): 887 (1995).
Coats, et al., “Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function,”Circulation, 85(6): 2119-2131 (1992).
Elmslie, et al., “Blocking by spironolactone (SC 9420) of the action of aldosterone upon the intestinal transport of potassium, sodium, and water,”Gut, 7(6): 697-9 (1966).
Hoshino, et al., “Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist,”J. Parma. Exp. Ther., 286(2): 643-649 (1998).
Ponikowski, et al., “Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy,”Am. J. Cardiol., 79(12): 1645-1650 (1997).
The RALES Investigators, “Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The randomized aldactone evaluation study [RALES]),”Am. J. Cardiol., 78:902-907 (1996).
Van De Borne, et al., “Relationship between repeated measures of hemodynamics, muscle sympathetic nerve activity, and their spectral oscillations,”Circulation, 96(12): 4326-4332 (1997).
Aarsland, et al., “Beta-blockade lowers peripheral lipolysis in burn patients receiving growth hormone. Rate of hepatic very low density lipoprotein triglyceride secretion remains unchanged”,Ann. Surg., 223(6):777.89 (1996).
Anker & Coats, “Cardiac Cachexia. A syndrome with impaired survival and immune and neuroendocrine activation,”Chest115:836-847 (1999).
Anker & Rauchhaus, “Insights into the pathogenesis of chronic heart failure: immune activation and cachexia,”Curr Opin Cardiol14(3):211-216 (1999).
Anker, “Catecholamine levels and treatment in chronic heart failure,”Eur. Heart J.19(Suppl F.):56-61 (1998).
Anker, “Relation between serum urice acid and lower limb blood flow in patients with chronic heart failure,”Heart78:39-43 (1997).
Anker, et al., “Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure,”European Heart Journal20:683-693 (1999).
Anker, et al., “Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia,”Circulation96:526-534 (1998).
Anker, et al., “Loss of bone mineral in patients with cachexia due to chronic heart failure,”Am J Cardiol83:612-615 (1999).
Anker, et al., “The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure,”European Heart Journal18:259-269 (1997).
Anker, et al., “Tumor necrosis factor and steroid metabolism in chronic heart failure: Possible relation to muscle wasting,”J Amer Coll Cardiol30:997-1001 (1997).
Anker, et al., “Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure,”Q. J. Med.91:199-203 (1998).
Benedict & Grahame-Smith, “Plasma adrenaline and noradrenaline concentrations and dopamine-b-hydroxylase activity in myocardial infarction with and without cardiogenic shock,”British Heart Journal42:214-220 (1979).
Berne, “Effect of epinephrine and norepinephrine on coronary circulation,”Circ Res6:644-655 (1958).
Besarb, et al., “The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epotein,”N Eng J Med339(9):584-590 (1998).
Brink, et al., “Angiotension II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism,”J Clin Invest97(11):2509-2516 (1996).
Brooks, et al., “Sympathetic activation of brown-adipose-tissue thermogenesis in cachexia”,Biosci. Rep., 1(6):509-17 (1981).
Chilain, et al., “Adrenergic coronary tone during submaximal exercise in the dog is produced by circulating catecholamines,”Cir Res58:68-82 (1986).
Chua, et al., “Relation between chemosensitivity and the ventilatory response to exercise in chronic heart failure,”J Am Coll Cardiol27:650-657 (1996).
Coats, “Symptoms and quality of life in heart failure: the muscle hypothesis,” “Symptoms and quality of lifein heart failure: the muscle hypothesis,”Br. Heart J72:S36-S39 (1994).
Coats, et al., “Prevention and reversal of cardiac cachexia in patients with severe heart failure by carvedilol: Results of the COPERNICUS study”,Scientific Sessions 2001 of the American Heart Association Supplement, 104(17): II-437 (2001).
Coombes, et al., “Changes in thermogenesis and brown fat activity in response to tumour necrosis factor in the rat”,Biosci. Rep., 7(10):791-9 (1987).
Cowie, et al., “The epidemiology of heart failure,”European Heart Journal18:208-225 (1997).
Daneryd, et al., “Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: A randomized prospective study,”Cancer Res.58(23):5374-5379 (1998).
Davenport, “Characteization of [125I]-PD164333, an ETAselective non-pepti
Anker Stefan Dietmar
Coats Andrew Justin Stewart
Bunner Bridget E
Hamud Fozia M
Imperial Innovations Limited
Pabst Patent Group LLP
LandOfFree
Methods of treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4214418